These findings suggest that the NINJ2/periostin/VAV2 signaling axis plays a crucial role in mediating chemoresistance and highlight the potential of targeting this pathway to enhance the response to ECF therapy in gastric cancer. This evidence concerns the gene NINJ2 and gastric cancer.